Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) saw a significant decline in short interest in July. As of July 31st, there was short interest totaling 3,770 shares, a decline of 51.8% from the July 15th total of 7,824 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.
Innate Pharma Stock Performance
Shares of OTCMKTS IPHYF remained flat at $1.65 during mid-day trading on Monday. The stock’s 50-day moving average is $1.65 and its 200 day moving average is $1.77. Innate Pharma has a 1 year low of $1.37 and a 1 year high of $2.25.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
See Also
- Five stocks we like better than Innate Pharma
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
